🇺🇸 FDA
Pipeline program

PF-06821497, Tablet to match Placebo for PF-06821497 250mg, PF-06821497, ENZALUTAMIDE, Tablet to match Placebo for PF-06821497 125mg

C2321003

Phase 3 small_molecule active

Quick answer

PF-06821497, Tablet to match Placebo for PF-06821497 250mg, PF-06821497, ENZALUTAMIDE, Tablet to match Placebo for PF-06821497 125mg for METASTATIC CASTRATION RESISTANT PROSTATE CANCER is a Phase 3 program (small_molecule) at Pfizer Ireland Pharmaceuticals Unlimited Company with 1 ClinicalTrials.gov record(s).

Program details

Company
Pfizer Ireland Pharmaceuticals Unlimited Company
Indication
METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials